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Background/aim: Vitamins and minerals are thought to play an essential but not entirely clear role in developing, preventing, and
treating nonscarring alopecia. Telogen effluvium, androgenetic alopecia, and alopecia areata are the most common forms of nonscarring
alopecias. We would like to present a different perspective on laboratory abnormalities in patients with nonscarring alopecia.
Materials and methods: A total of 467 patients (287 females, 180 males) were included retrospectively: One hundred and sixty patients
in the telogen effluvium group, 101 patients in the androgenetic alopecia group, 99 patients in the alopecia areata group, and 107 patients
in the hair loss group (patients who could not be diagnosed with any nonscarring alopecia and wanted to have an analysis due to the
complaint of hair loss). Sociodemographic data, diagnostic distribution, and laboratory findings (hemoglobin, ferritin, vitamin B12,
vitamin D, and TSH) were evaluated and compared.
Results: The most common diagnosis was telogen effluvium in females and androgenetic alopecia in males. In women, hemoglobin
(12.2% vs. 1.1%) and ferritin deficiencies (22.3% vs. 8.9%) were significantly higher than in men (p < 0.001, p < 0.001) Ferritin,
hemoglobin, and vitamin B12 levels were significantly lower, and the number of patients with vitamin D, ferritin, hemoglobin and
vitamin B12 deficiencies were significantly higher in the telogen effluvium group compared to the other groups. Laboratory abnormalities
were detected least in the hair loss group.
Conclusion: The number of patients with the highest abnormalities in all parameters was observed in the telogen effluvium group
and females; therefore, we mainly suggest examining female patients with telogen effluvium first. We may prefer not to immediately
investigate the laboratory abnormalities and follow up patients with some treatments in the hair loss group.
Key words: Alopecia areata, androgenetic alopecia, anemia, ferritin, telogen effluvium, vitamin D

1. Introduction
Hair loss is a widespread problem that concerns
individuals of all ages. Patients who apply to dermatology
outpatient clinics with this complaint constitute a
significant part of our daily practice and are examined
under two main headings, mainly nonscarring and
scarring alopecia. Telogen effluvium (TE), androgenetic
alopecia (AGA), and alopecia areata (AA) are the most
common forms of nonscarring alopecias [1]. There are
studies with conflicting results on the role of vitamin and
mineral deficiencies, anemia, and thyroid dysfunction in
nonscarring alopecia [2–7]. There is a general view that
hair loss can be caused by vitamin deficiency, and patients
who apply with hair loss complaints demand that vitamin
values be investigated.
In this study, demographic data, diagnostic distribution,
and laboratory parameters of patients diagnosed with
nonscarring alopecia were evaluated. Patients were

grouped according to diagnosis and statistically compared.
We aimed to provide solutions to the question of “Which
laboratory analysis should we perform at first on whom in
patients with nonscarring alopecia?”
2. Materials and methods
A retrospective study was planned to evaluate the patients
admitted with nonscarring hair loss complaints or
diagnosed with nonscarring alopecia. We enrolled 467
patients from dermatology outpatient clinics of Mareşal
Çakmak State Hospital and Regional Training and Research
Hospital, Erzurum, Turkey, between November 2018 and
January 2021. All patients were evaluated and diagnosed
by the same dermatologist (Ü.Ö.). The study was approved
by the ethics committee of Regional Training and Research
Hospital, Erzurum, Turkey (decision no: 2021/01-12).
Age, sex, primary diagnoses, and laboratory findings
were obtained from the electronic registration database.
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One hundred seven patients who cannot be diagnosed
with any form of nonscarring alopecia and wanted to
have an analysis due to hair loss complaints were included
in the Hair Loss (HL) group. Moreover, 360 patients
diagnosed with nonscarring alopecia (160 TE, 101 AGA,
and 99 AA) were involved in the study. Levels of vitamin D
(kit catalog no: 10995720), hemoglobin (Lysercell WDF®
solution kit catalog no: AL-337-564), ferritin (kit catalog
no: 10995568), vitamin B12 (kit catalog no: 10995715),
and TSH (kit catalog no: 10995704) were measured by
Atellica Solution Immunoassay, Siemens, USA.
The patients were diagnosed with TE, AGA, and
AA based on the data obtained from anamnesis,
dermatological, and trichoscopic examination. Since TE
can usually be triggered by an etiological factor, systemic
disease, fever, surgeries, medications, diet, postpartum
period, and stress were questioned. In dermatological
examination, a hair-pulling test, which is an important
clue for particularly TE, was performed for each patient.
Also, trichoscopic findings were evaluated. Hair diameter
diversity, peripilar sign (perifollicular pigmentation),
and yellow dots are trichoscopic features of AGA. In AA,
black dots, tapering hairs, broken hairs, yellow dots, and
short vellus hairs are observed, and black dots, tapering
hairs, and broken hairs are considered as pathognomonic
findings [8].
Reference ranges of hematinic parameters were
accepted as follows: hemoglobin (M: 13- 17.8 g/dL, F: 12.2–
15.9 g/dL), ferritin (M: 30- 400 ng/mL, F: 11–150 ng/mL),
vitamin B12 (197–771 ng/mL), vitamin D (20–70 ng/mL),
TSH (0.27–4.20 uUI/mL). Patients with abnormal TSH
levels (<0.27,> 4.20 uUI/mL) were investigated for free
thyroxine (FT4), free triiodothyronine (FT3) and then the
decision was made for hypotrioidism or hyperthyroidism.
Statistical Package for Social Sciences (SPSS Inc,
Chicago, IL, USA) for Windows 22.0 program was used
for statistical analysis. Chi-square test was used to compare
categorical data. Chi-square test was used to compare
groups according to sex and hematinic parameters, as well
as to compare sexes according to hematinic parameters.
After the chi-square analysis, paired comparisons were
made, and Bonferroni correction was made to determine
the group from which the difference originated. The
suitability of the parameters to the normal distribution
was evaluated with the Kolmogorov-Smirnov test. While
evaluating the study data, in addition to descriptive
statistical methods (mean, standard deviation, number,
and percentage), the One-Way ANOVA test was used
for comparisons of parameters normally distributed
in quantitative data. One Way ANOVA test was used
to compare the groups in terms of age and hematinic
parameters. Post-hoc test (Tukey test) was used to find out
where significance originated. The value of p < 0.05 was
considered statistically significant.

3. Results
A total of 467 individuals, 287 females (61.4%) and 180
males (38.6%), applied with the complaint of hair loss
between the ages of 2–58 years and were examined due
to nonscarring alopecia were included in our study
retrospectively. One hundred and sixty patients (34.2%)
were diagnosed with TE, 101 patients (21.6%) AGA, 99
patients (21.1%) AA, and 107 patients (22.9%) as HL.
While TE and HL diagnoses were higher in females, the
male sex was more dominant in AGA and AA groups. The
age and sex distribution of the groups is shown in Table 1.
Vitamin D deficiency in 345 patients (73.8%),
hemoglobin deficiency in 37 patients (7.9%), ferritin
deficiency in 80 patients (17.1%), vitamin B12 deficiency
in 54 patients (11.5%), thyroid dysfunction in 31 patients
(6.6%) were detected. At least a hematinic deficiency was
present in 143 patients (89.4%) in the TE group, 84 patients
(83.2%) in the AGA group, 77 patients (77.8%) in the AA
group, and 70 patients (65.4%) in the HL group.
The deficiency of at least one of the hematinic values
was found as 81.5% in women and 77.8% in men. The
most common deficiency was observed in both sexes was
vitamin D deficiency (Table 2). The second was ferritin
deficiency in women and vitamin B12 deficiency in men.
In women, hemoglobin deficiency (12.2% vs. 1.1%) and
ferritin deficiency (22.3% vs. 8.9%) were significantly
higher than in men (p < 0.001, p < 0.001, Table 2).
Mean values of hematinic parameters were given in
Table 3, and a comparison of groups according to the
number of patients with hematinic deficiencies was given
in Table 4.
3.1. Vitamin D
The mean vitamin D levels in all groups were found
below the reference range: TE (14.6 ± 11.1 ng/mL), AGA
(16.2 ± 8.4 ng/mL), AA (15.7 ± 9.6 ng/mL), HL (17, 9
± 11.3 ng/mL) (p= 0.086, Table 3). Vitamin D deficiency
was detected in 127 patients (79.4%) in the TE group, 79
patients (78.2%) in the AGA group, 70 patients (70.7%)
in the AA group, 69 patients (64.5%) in the HL group
(Table 4, Figure). The number of patients with vitamin D
deficiency was significantly higher in the TE group (p=
0.031, Table 4).
3.2. Hemoglobin
The mean hemoglobin of the groups was 13.5 ± 1.6 g/
dL in the TE group, 16.1 ± 1.4 g/dL in the AGA group,
15.4 ± 1.54 g/dL in the AA group, 14.8 ± 1.4 g/dL in
the HL group (p < 0.001, Table 3). Hemoglobin deficiency
was detected in 32 patients (20%) in the TE group, four
patients (4%) in the AA group, and one patient (0.9%)
in the HL group (Table 4). No hemoglobin deficiency
was found in the patients with AGA (Figure). The mean
hemoglobin in the TE group was significantly lower, and
the number of patients with hemoglobin deficiency was
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Table 1 Sociodemographic data of the groups.
Age
(years)

Age range
(years)

M ± SD

Female

Male

n

%

Total

n

%

n

TE

27.7 ± 8.8a

7–55

156

97.5a

4

2.5

160

AGA

25.6 ± 7.3

15–50

25

b

24.8

76

75.2

101

AA

26.1 ± 12.3a

2–58

25

25.3b

74

74.7

99

HL

21.4 ± 9.2

2–55

81

75.7

26

24.3

107

Total

25.5 ± 9.7

2–58

287

61.4

180

38.6

467

p

<0.001*

a

b

c

<0.001**

M ± SD: Mean ± Standart deviation, n: Number, *One Way ANOVA test, **Chi-square test (comparison
of groups according to sex), a,b,c: Different letters indicate the statistical difference.
Table 2 Comparison of hematinic deficiencies and thyroid dysfunction in all patients
according to sex.
Vitamin D
deficiency

Hemoglobin
deficiency

Ferritin
deficiency

Vitamin B12
deficiency

Thyroid
dysfunction

n

%

n

%

n

%

n

%

n

%

Female

215

74.9

35

12.2

64

22.3

33

11.5

22

7.7

Male

130

72.2

2

1.1

16

8.9

21

11.7

10

5.6

p*

0.519

<0.001

<0.001

0.956

0.380

* Chi square test, n: Number
Table 3 Comparison of hematinic parameters in groups.
Vitamin D (ng/mL)

Hemoglobin (g/dL)

Ferritin (ng/mL)

Vitamin B12 (pg/mL)

TSH (UI/mL)
M ± SD

M ± SD

M ± SD

M ± SD

M ± SD

TE

14.6 ± 11.1

13.5 ± 1.6a

28.3 ± 37.4a

317.7 ± 134.4a

2.2 ± 1.6

AGA

16.2 ± 8.4

16.1 ± 1.4

100.0 ± 84.7

316.8 ± 170.5

2.1 ± 1.4

AA

15.7 ± 9.6

15.4 ± 1.5c

93.5 ± 103.9b

344.6 ± 150.4a,b

2.3 ± 2.0

HL

17.9 ± 11.3

14.8 ± 1.4

59.3 ± 47.6

377.1 ± 154.9

2.2 ± 1.1

p*

0.086

<0.001

<0.001

0.007

0.943

b

d

b

c

a

b

*One Way ANOVA test, a,b,c,d: Different letters indicate the statistical difference, M ± SD: Mean ± Standart deviation.

significantly higher than the other groups (p < 0.001, p <
0.001, Table 3,4).
3.3. Ferritin
The mean ferritin values were 28.3 ± 37.4 ng/mL in the
TE group, 100.0 ± 84.7 ng/mL in the AGA group, 93.5
± 103.9 ng/mL in the AA group, and 59.3 ± 47.6 ng/mL
in the HL group (p < 0.001, Table 3). Ferritin deficiency
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was detected in 53 patients (33.1%) of the TE group, eight
patients (7.9%) of the AGA group, 13 patients (13.1%) of
the AA group, and six patients (5.6%) of the HL group
(Table 4, Figure). Ferritin levels were significantly lower in
the TE group than the other groups, and the number of
patients with ferritin deficiency was significantly higher (p
< 0.001, p < 0.001, Table 3.4).
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Table 4 Comparison of the groups according to hematinic deficiencies and thyroid dysfunction.
Vitamin D
deficiency

Hemoglobin
deficiency
n

Ferritin
deficiency
n

%

n

%

20.0

15

9.4

10.9a,b

6

5.9

8

8.1

8

8.1

3

2.8b

3

2.8

%

TE

127

79.4

32

20.0

53

33.1

32

AGA

79

78.2a,b

0

0.0b

8

7.9b

11

AA

70

70.7

4

b

4.0

13

13.1

HL

69

64.5b

1

0.9b

6b

5.6b

p*

0.031

a,b

a

<0.001

a

b

<0.001

Thyroid
dysfunction
n

n

a

%

Vitamin B12
deficiency
%
a

a,b

<0.001

0.194

*Chi square test, a,b: Different letters indicate the statistical difference, n: Number

Figure. Low or normal/high ratios of hematinic parameters in all groups.

3.4. Vitamin B12
The mean vitamin B12 levels in all groups were in the
reference range given as follows: TE (317.7 ± 134.4 pg/mL),
AGA (316.8 ± 170.5 pg/mL), AA (344.6 ± 150.4 pg/mL),
HL (377.1 ± 154.9 pg/mL) (p= 0.007, Table 3). Vitamin B12
deficiency was detected in 32 patients (20%) in the TE group,
11 patients (10.9%) in the AGA group, eight patients (8.1%)
in the AA group, and three patients (2.8%) in the HL group
(Figure). Mean vitamin B12 levels were significantly lower in
the TE and AGA groups compared to the AA and HL groups,
while the number of patients with vitamin B12 deficiency
was significantly higher only in the TE group compared to
the other groups (p= 0.007, p < 0.001, Table 3,4).

3.5. Thyroid Stimulating Hormone
The mean of TSH levels were 2.2 ± 1.6 UI/mL in the
TE group, 2.1 ± 1.4 UI/mL in the AGA group, 2.3 ±
2.0 UI/mL in the AA group, 2.2 ± 1.1 UI/mL in the
HL group (p= 0.943, Table 3). Twelve patients in the
TE group had hypothyroidism, and three patients
had hyperthyroidism. Six patients in the AGA group
had hypothyroidism, and none of the patients had
hyperthyroidism. Seven patients in the AA group had
hypothyroidism, and one patient had hyperthyroidism.
Three patients in the HL group had only hypothyroidism.
There was no significant difference between the groups
in thyroid dysfunction (Table 4).
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4. Discusson
Vitamin-mineral deficiencies and laboratory abnormalities
are often mentioned in nonscarring alopecia, and there
is still no consensus on the exact date. Vitamins and
minerals are thought to play an essential but not entirely
clear role in the hair follicle cycle, and their deficiencies
may be associated with a modifiable risk factor in the
development, prevention, and treatment of alopecia [1].
In our study, patients presented with nonscarring hair
loss were grouped according to diagnosis (TE, AGA, AA,
HL), and demographic data, and laboratory parameters
(hemoglobin, ferritin, vitamin B12, vitamin D, thyroid
function) were evaluated in each group. The patients
were diagnosed with TE, HL, AGA, and AA in order of
frequency. The most common diagnosis was TE in females
and AGA in males. It was observed that the female/male
ratio of patients was 1.5/1, and the mean age was in the 3rd
decade in all groups. In the HL group, patients under 30
(%85) were the most common. Laboratory abnormalities
were detected least in the HL group and the most in the
TE group.
A recent review suggested that iron deficiency is more
common in female patients with non-scarring alopecia,
iron supplementation in TE or AGA, and vitamin D
supplementation in TE, AGA, and AA may be beneficial.
However, they suggested insufficient evidence for vitamin
B12 supplementation in TE, AGA, or AA [1]. In our
study, the mean vitamin D levels in all groups were below
the reference range, and the most common deficiency
was vitamin D deficiency (73.8%). After administering
vitamin D to mice with congenital alopecia, Vegesna et
al. observed that hair growth was stimulated dramatically,
and expression of certain keratins (Ha7, Ha8, and Hb3)
increased. They stated that vitamin D might affect
keratinocytes to stimulate hair growth and initiate the hair
follicle cycle [9]. It has also been reported that as vitamin
D levels decreased in TE, AGA, and AA, the severity of the
disease increased [3,10]. On the contrary, some authors
reported that the vitamin D levels of patients with AA
and the control group were similar, and there was no
relationship between AA and vitamin D [11].
In a study evaluating vitamin D levels and anemia,
vitamin D levels were significantly higher in patients with
TE than controls, and it was suggested that this might be
associated with increased exposure to ultraviolet light due
to TE. Ferritin and hemoglobin levels were significantly
lower in patients, and the authors pointed out that iron
deficiency anemia may be the main trigger factor in
TE [12]. In our study, the most common deficiency
1

after vitamin D deficiency was ferritin deficiency. Iron
deficiency has often been associated with nonscarring
alopecia, particularly TE. Serum ferritin (<41 ng/mL) is
considered one of the most sensitive and specific markers
for iron deficiency [13].1 The ferritin level to employ in
patients with hair loss has not been determined yet, but
70 µg/L, with a normal erythrocyte sedimentation rate
(<10 mm/h), has been recommended [6]. In our study,
the mean ferritin was lower than 40 ng/mL in only the TE
group. The rate of patients with ferritin level <40 ng/mL
was 126/160, and the rate of patients with ferritin level <70
ng/mL was 150/160 in the TE group. In both cases where
the cut-off level was 40 or 70 ng/mL, ferritin deficiency
was most observed in the TE group.
However, some studies proposed different results, such
as low ferritin level, associated with dense hair loss rather
than mild hair loss or no relationship between ferritin
deficiency and alopecia [4,14,15]. Kantor et al. found
serum ferritin significantly lower in AGA and AA than the
control group but not in TE [14]. However, in this study,
the mean age of the TE group was 47.9 and higher than
other groups. Postmenopausal female patients were more
likely to be in the TE group due to the higher mean age,
and this probability may be the reason for the high ferritin
levels [15]. In a study similar to our results, it was reported
that iron deficiency anemia could not be detected in any
male and female patients diagnosed with AGA [2]. In our
study, low hemoglobin was detected in none of the patients
with AGA, the mean ferritin was found higher than 70 ng/
mL, and the number of patients with ferritin deficiency
(8/101) was quite low in the AGA group. In conclusion,
we suggest that AGA may not be associated with iron
deficiency and anemia.
As we compared our results with a retrospective study
conducted with AA patients, the male/female ratio in
our study was higher (2.9 vs. 1.8), and the mean age was
younger (26.1 vs. 29.6). Hemoglobin deficiency (4% vs.
11.1%) and thyroid dysfunction (8% vs. 10%) were less
common in our study, while ferritin (13.1% vs. 10.6%)
and vitamin B12 deficiencies (8.1% vs. 3.9%) were more
common [5]. Our results suggested that AA may be
associated with ferritin deficiency rather than anemia,
but a study, comparing ferritin, iron, and iron-binding
capacities between AA patients and controls, reported no
association between iron deficiency and AA [16].
Vitamin B12 is suggested to have a role in hair follicle
proliferation, as it is essential for DNA synthesis [17-18].2
However, there is still no sufﬁcient data to recommend
supplementation of vitamin B12 in TE, AGA, and AA [1].
In a case-control study examining vitamin B12 deficiency

Schrier SL (2008). Causes and diagnosis of anemia due to iron deficiency [online]. Website: http://www.uptodate.com. [accessed September 2008].

Harvard TH Chan, School of Public Health (2018). Three of the B vitamins: folate, vitamin B6, and vitamin B12[online]. Website https://www.hsph.
harvard.edu/nutritionsource/vitamins/vitamin-b/ [Accessed 8 Aug 2018]
2
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in women with TE, there was no difference between the
groups in mean vitamin B12 levels, while the number of
patients with vitamin B12 deficiency (11.9% vs. 6.7%) was
significantly higher than controls [17]. In our study, mean
vitamin B12 levels were not below the reference range in
any group, and the highest number of patients with vitamin
B12 deficiency was in the TE group (%20). Contrary to
our results, in a study conducted with 563 TE patients, the
number of patients with vitamin B12 deficiency (3%) was
found to be quite low [19]. In a case-control study, Gönül
et al. found no significant difference in vitamin B12 levels
between AA patients and controls; thus, they reported that
vitamin B12 does not play a role in the etiology and activity
of AA [20]. However, the number of individuals with
vitamin B12 deficiency was not presented in the report and
can be a limitation of this study.
Thyroid hormones are necessary for the normal cycle
of hair and normal sebum secretion [21]. Hale and Ebling
showed the effect of thyroid hormone on the hair growth
cycle in rats given intraperitoneal Thyroxine (T4) and
reported that T4 decreased both the anagen phase and the
telogen phase [22]. In addition, the T3 hormone has been
shown to stimulate the proliferation or metabolism of outer
root sheath keratinocytes, dermal papilla cells, and sheath
cells of hair follicles [23]. Diffuse non-cicatricial alopecia,
loss of pigment in the hair, and premature graying may
occur in individuals with thyroid dysfunction [24,25].
The highest number of patients with thyroid dysfunction
was in the TE group (9.4%), and the second was in the AA
group (8.1%) in our study. Already, in the literature, thyroid
dysfunction has been mostly associated with TE and AA. In
a study conducted with 151 TE patients, thyroid dysfunction
was found in 23 patients (15.2%), and it was suggested that

thyroid dysfunction might be related to TE [7]. A recent
meta-analysis stated that the prevalence of thyroid diseases
in AA patients was significantly higher than in controls,
and it was recommended that AA patients be examined for
thyroid diseases [26]. It is suggested to investigate thyroid
autoantibodies to determine those with a risk of thyroid
disease, even if patients with AA are euthyroid [25]. As a
result, it should be helpful to examine patients with TE and
AA for thyroid dysfunction.
In this study, the relationship between hair loss and
laboratory abnormalities, which continues to be discussed
and still has no definitive results, was examined. Solutions
were offered to the question of which laboratory examination
should be done on which patient. We may prefer not to
investigate the laboratory abnormality immediately and
follow up patients with the treatments given initially in
young patients admitted due to hair loss but do not have
the necessary criteria for any diagnosis of nonscarring
alopecia (TE, AGA, or AA). The number of patients with
the highest abnormalities in all parameters was observed
in TE and females; therefore, we particularly suggest
examining patients with TE and female patients first. More
studies had been reported on laboratory abnormalities in
TE, and they may also support our suggestion [12,17,17,27–
29]. After vitamin D deficiency in both sexes, investigation
ferritin and hemoglobin deficiency in females and
vitamin B12 deficiency in males may be recommended.
Limitations of our study were that a control group could
not be formed as there was no homogeneous distribution in
sociodemographic data in the groups, and it included only
patients in a particular region retrospectively. Multicenter
studies conducted with control groups in different regions
will contribute more to revealing precise results.
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